![Ac-[Nle4,D-Phe7]-α-MSH (4-10)-NH2](/upload/1124/V71949.png)
| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
This peptide is an agonist at melanocortin receptors (MCRs), specifically designed to interact with multiple subtypes including hMC1R, hMC3R, hMC4R, and hMC5R. The amino acid substitutions at positions 4 (Nle) and 7 (D-Phe) are critical for conferring enhanced potency and stability compared to the native alpha-MSH peptide, making it a superpotent agonist.
|
|---|---|
| ln Vitro |
In Cloudman S91 murine melanoma cells, Ac-[Nle4,D-Phe7]-α-MSH (4-10)-NH2 (0.1 pM-1 μM; 48 h) promotes tyrosinase activity in a dose-dependent manner[1].
In vitro, Ac-[Nle4,D-Phe7]-alpha-MSH (4-10)-NH2 is known to stimulate tyrosinase activity. Tyrosinase is the key enzyme in melanin synthesis, and its activation demonstrates the peptide's functional agonist activity at the MC1 receptor, which is primarily expressed on melanocytes. This functional assay is a standard method to confirm melanocortin receptor activation. |
| ln Vivo |
In rats, the combination of Ac-[Nle4,D-Phe7]-α-MSH (4-10)-NH2 (0-50 pM; icv; single dose) had a thermoregulatory effect[2].
In vivo, this melanotropin peptide exhibits a thermoregulatory effect in rat models. This specific activity is mediated through central melanocortin receptors, particularly MC4R, which is a key regulator of body temperature. The demonstration of this effect confirms that the peptide is able to reach its central targets and initiate a physiological response following administration. |
| Enzyme Assay |
A standard non-cellular protocol involves radioligand binding assays using membrane preparations from cells expressing cloned human melanocortin receptors. The peptide is incubated with 125I-NDP-alpha-MSH, a radioactive tracer, and the membrane preparation. After incubation, the bound and free ligand are separated by filtration. Radioactivity is counted, and competitive binding curves are generated to determine the peptide's affinity (Ki).
|
| Cell Assay |
The cellular activity of this peptide is typically measured in B16-F10 mouse melanoma cells. Cells are seeded in 96-well plates and treated with various concentrations of the peptide (e.g., 1 nM to 1 uM). After 72 hours of incubation, tyrosinase activity is quantified by measuring the oxidation of L-DOPA. Protein concentration is determined, and the melanin content is measured at 405 nm to assess the biological response.
|
| Animal Protocol |
Animal/Disease Models: Rat model[2]
Doses: 0, 0.5, 1, 5, 10, or 50 pM peptide in 0.5 μL sterile saline Route of Administration: Intracerebroventricular injection in the anterior hypothalamic-preoptic area (AHPOA) of rats; single dose; recorded 0, 10, 20, 30, 40 , 50, and 60 min after injection Experimental Results: demonstrated greater difference than mean temperatures of animals receiving sterile saline group. For in vivo studies, the peptide is typically dissolved in sterile saline. Male Sprague-Dawley rats are injected intracerebroventricularly (ICV) with a small volume (e.g., 10 uL containing 1-10 ug of the peptide). Core body temperature is monitored via a rectal probe at regular intervals (e.g., every 15 minutes) for 2-4 hours post-injection. A decrease in body temperature compared to vehicle-injected controls indicates a thermoregulatory response. |
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for this peptide is not provided. As a peptide, it is susceptible to rapid proteolytic degradation in vivo, leading to a short half-life. This is a common challenge for peptide-based research tools. The primary route of degradation is via peptidases in the blood and tissues, which cleave the peptide bonds, leading to loss of biological activity.
|
| Toxicity/Toxicokinetics |
Standard toxicological data for this peptide is not detailed in these references, as it is a research tool. For in vivo experiments, common signs of acute toxicity or distress (e.g., changes in locomotor activity, piloerection, convulsions) are monitored. No severe adverse effects have been reported at the doses typically used for melanocortin research.
|
| References | |
| Additional Infomation |
This compound is a key example of a "superpotent" melanocortin agonist. Its stability and potency have made it a standard in the field for almost three decades. Studies have investigated how substituting specific amino acids (like at position 7) can switch the pharmacology from an agonist to an antagonist at specific melanocortin receptors, making it a versatile scaffold for drug discovery.
|
| Molecular Formula |
C47H64N14O10
|
|---|---|
| Molecular Weight |
985.09886932373
|
| Exact Mass |
984.492
|
| CAS # |
82188-67-8
|
| PubChem CID |
10290587
|
| Appearance |
White to off-white solid powder
|
| LogP |
-0.2
|
| Hydrogen Bond Donor Count |
13
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
30
|
| Heavy Atom Count |
71
|
| Complexity |
1850
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C(N)(=O)CNC(=O)[C@H](CC1C2=C(C=CC=C2)NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CC1N=CNC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCC)NC(C)=O
|
| InChi Key |
ZHFBHJALAOQGNU-ZPRVLUMXSA-N
|
| InChi Code |
InChI=1S/C47H64N14O10/c1-3-4-14-33(56-27(2)62)42(67)58-35(17-18-40(64)65)44(69)61-38(22-30-24-51-26-55-30)46(71)59-36(20-28-11-6-5-7-12-28)45(70)57-34(16-10-19-52-47(49)50)43(68)60-37(41(66)54-25-39(48)63)21-29-23-53-32-15-9-8-13-31(29)32/h5-9,11-13,15,23-24,26,33-38,53H,3-4,10,14,16-22,25H2,1-2H3,(H2,48,63)(H,51,55)(H,54,66)(H,56,62)(H,57,70)(H,58,67)(H,59,71)(H,60,68)(H,61,69)(H,64,65)(H4,49,50,52)/t33-,34-,35-,36+,37-,38-/m0/s1
|
| Chemical Name |
(4S)-4-[[(2S)-2-acetamidohexanoyl]amino]-5-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0151 mL | 5.0756 mL | 10.1513 mL | |
| 5 mM | 0.2030 mL | 1.0151 mL | 2.0303 mL | |
| 10 mM | 0.1015 mL | 0.5076 mL | 1.0151 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
